TARC varies significantly among patients of different ages, nevertheless, age has little influence on SCCA2, which is more convenient for clinical application, so SCCA2 is considered superior to TARC and IgE in the severity assessment of AD in children (55, 56). Here, IGHE is linked to Alzheimer disease.